Active — Not RecruitingNot Applicable

Noninvasive Mapping Before Surgical Ablation

Austria51 participantsStarted 2017-01-13

Plain-language summary

The purpose of this study is to assess the electrophysiological mechanism of atrial fibrillation by means of a beat-to-beat noninvasive 3D mapping method in patients with concomitant persistent and long-standing persistent atrial fibrillation undergoing surgical ablation.

Who can participate

Age range

18 Years – 90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * legal age (18-90a) * life expectancy \> 2 years * patients suffering from persistent and long standing atrial fibrillation * scheduled for concomitant surgical ablation * possibility to follow-up * given informed consent Exclusion Criteria: * vulnerable patient groups * pregnancy * any previous surgical ablation * acute surgical indications * any physical condition that leads to a life expectancy of less than two years * any contraindication to the treatments necessary for the trial's conduction as e.g. * known allergic reaction to contrast agent * known allergic reaction to antiarrhythmic drugs * claustrophobia or anxiety in small spaces * severe renal impairment * unmanageable hyperthyroidism * participation in any other clinical trial that either excludes enrolment or may be a confounding factor to results * voluntary retention

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The patients electrophysiological mapping results acquired with ECGI will be analyzed: Number and distribution of rotor and focal activities will be measured.

Timeframe: Prior to the planned procedure.

Trial details

NCT IDNCT06803615

SponsorMedical University of Vienna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01-01

View on ClinicalTrials.gov More Atrial Fibrillation (AF) trials

Who can participate

Age range

18 Years – 90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.